Skip to main content
NCBI home page
Journal of Intercultural Ethnopharmacology logoLink to Journal of Intercultural Ethnopharmacology
. 2016 Aug 14;5(4):343–349. doi: 10.5455/jice.20160731025522

In vitro xanthine oxidase and albumin denaturation inhibition assay of Barringtonia racemosa L. and total phenolic content analysis for potential anti-inflammatory use in gouty arthritis

Nurul Izzati Osman 1,✉, Norrizah Jaafar Sidik 1, Asmah Awal 2, Nurul Athirah Mohamad Adam 1, Nur Inani Rezali 1
PMCID: PMC5061476  PMID: 27757263

Abstract

Aim:

This study was conducted to evaluate the in vitro anti-inflammatory activities and total phenolic content (TPC) of methanolic extracts of infloresence axes, endosperms, leaves, and pericarps of Barringtonia racemosa L.

Methods:

The anti-inflammatory study was conducted by assessing the potential through xanthine oxidase (XO) and albumin denaturation inhibition assays. Meanwhile, the TPC in the extracts were assessed by Folin-Ciocalteu assay.

Results:

In the XO inhibition assay, the infloresence axes extract was found to exert the highest inhibition capacity at 0.1% (w/v) with 59.54 ± 0.001% inhibition followed by leaves (58.82 ± 0.001%), pericarps (57.99 ± 0.003%), and endosperms (57.20 ± 0.003%) extracts. Similarly in the albumin denaturation inhibition assay, the infloresence axes extract had shown the greatest inhibition capacity with 70.58 ± 0.004% inhibition followed by endosperms (66.80 ± 0.024%), leaves (65.29 ± 0.006%), and pericarps extracts (43.33 ± 0.002%). Meanwhile, for TPC analysis, leaves extract was found to have the highest phenolic content (53.94 ± 0.000 mg gallic acid equivalent [GAE]/g DW) followed by infloresence axes (31.54 ± 0.001 mg GAE/g DW), endosperms (22.63 ± 0.001 mg GAE/g DW), and the least was found in pericarps (15.54 ± 0.001 mg GAE/g DW).

Conclusion:

The results indeed verified the in vitro anti-inflammatory activities of B. racemosa and supported its potential to be used in alleviating gouty arthritis and XO-related diseases.

KEY WORDS: Anti-inflammatory activity, Barringtonia racemosa, protein denaturation inhibition, total phenolic content, xanthine oxidase inhibition

INTRODUCTION

According to the data from the World Health Organization, the value of worldwide annual market for herbal medicinal products approaches US$60 billion [1]. Modern science has proven that the association of plants in medicinal approach is scientifically sound due to the bioactive compound constituents in plants which later paved the way for further discovery of drug developments from plants.

Barringtonia racemosa (L). which is also known as Putat, “fish poison” or “powder puff” is a type of plant species found to be widely distributed from Eastern Africa and Madagascar to Micronesian and Polynesian Island. Due to such diverse distribution, this species has been very well associated ethnobotanically in various tribes around the world. Pharmacologically, this species had been scientifically proven to possess various medicinal benefits [2], among which are antibacterial [3-5], anti-mycobacterial [6], and anti-fungal [4]. Apart from being proven to have anti-infective activities, B. racemosa also successfully showed promising anti-tumor [7] and anti-arthritic activities [8] with excellent analgesic [5,9,10] and antioxidant properties [11-13].

One of the most common and essential properties of secondary metabolites is anti-inflammatory activity. Inflammation is caused by release of chemicals from tissues and migrating cells [14]. The occurrence of inflammation has been regarded to be associated in a number of disorders and prominently related to the painful condition. Gouty arthritis has been identified to be the most common inflammatory arthritis in general practice and may significantly impair quality of life due to restricted mobility [15]. This study was carried out to evaluate the potential of B. racemosa to be used as a natural remedy for the treatment of inflammatory diseases. Particular focus on inflammatory gouty arthritis was emphasized since xanthine oxidase (XO) inhibitory activity assay was being scrutinized; wherein the XO has been identified as the culprit in gouty arthritis pathogenesis due to the formation of uric acid deposition in gouty patients.

MATERIALS AND METHODS

Sample Preparation and Extraction

The plant materials of B. racemosa were collected from Nasuha Herbal Farm, Johor, Malaysia. The determination of botanical term for plant parts used was made by referring to glossary of botanical terms [16] and Prance [17]. Four plant parts were studied which were infloresence axis, leaf [Figure 1], endosperm, and pericarp part of fruits [Figure 2]. The samples were air dried under the shade at ambient temperature ranging from 28°C to 32°C. The dried plant samples were further crushed into coarse powder using a domestic electric grinder (Philips, Netherlands). The extracts were prepared by soaking 5 g of samples in 200 ml of 70% methanol (Merck, Germany) diluted with 30% deionized water (Arium® pro Sartorius, Germany). The macerated samples were filtered using Whatman filter paper Number 1 (70 mm) (GE Healthcare, UK) placed on Buchner funnel whereby the filtration was assisted by a vacuum pump (GAST, USA). The resulting filtrates were then concentrated under vacuum using rotary evaporator system (Buchi, Switzerland) to yield concentrated extracts of samples. The resulting extracts were kept in glass vials and refrigerated at 4°C until further use.

Figure 1.

Figure 1

Open in a new tab

The (a) infloresence axis and (b) leaf of Barringtonia racemosa

Figure 2.

Figure 2

Open in a new tab

The (a) endosperm and (b) pericarp part of Barringtonia racemosa fruit

Anti-inflammatory Activity Assays

XO inhibitory activity of B. racemosa

The assay method was carried out according to Azmi et al. [18] with some modifications in which the positive standard used in the current study was oxypurinol. The concentrations of samples and standards used in the study were expressed in the form of a percentage (%). The plant extracts were prepared at a concentration of 0.1% each (1.0 mg/ml). The assay mixtures were prepared by adding 300 µl of 50 mM potassium phosphate buffer (pH 7.5), 100 µl sample solutions, 100 µl of freshly prepared XO enzyme solution (0.2 U/ml in phosphate buffer), and 100 µl of deionized water. The mixtures were incubated at 37°C for 15 min. Afterward, 200 µl substrate solution (0.15 mM of xanthine) will be added into the assay mixture and further incubated at 37°C for 30 min. The reaction was stopped by the addition of 200 µl of 0.5 M hydrochloric acid. The XO inhibitory activities were assayed spectrophotometrically at 295 nm (indication of uric acid formation at 25°C) using UV/vis spectrophotometer (Jasco V-630 Spectrophotometer, Japan), and the data were processed by Spectra Manager system. Oxypurinol (001 %) was used as a positive control. The assay mixture without sample extract served as a negative control. All assays were done in triplicate; thus, inhibition percentages are the mean of three observations. The XO inhibitory activities were expressed as the percentage of inhibition of XO, calculated as follows:

% XO inhibition = (1−B/A)×100%

Where B is the absorbance reading of the test sample, and A is the absorbance reading without test sample (negative control).

Various concentrations of 0.025%, 0.050%, 0.075%, and 0.100% of oxypurinol and the most optimum extract were evaluated for XO inhibitory activity. The dose-response graph was utilized to generate a linear equation to estimate the concentration at which maximal inhibition (100%) is obtained.

Albumin denaturation inhibitory activity of B. racemosa

The assay was carried out by adopting the methods described by Kumari et al. [19] with some modifications in which the volume of each component in the reaction mixtures was reduced by half. The plant extracts and positive standards (ibuprofen and diclofenac) were prepared at a concentration of 0.1% each (1.0 mg/ml). A reaction vessel for each mixture was prepared consisted of 200 µl of egg albumin, 1400 µl of phosphate buffered saline, and 1000 µl of the test extract. Distilled water instead of extracts was used as a negative control. Afterward, the mixtures were incubated at 37°C for 15 min and then heated at 70°C for 5 min. After cooling, their absorbances were measured at 660 nm (Jasco V-630 Spectrophotometer, Japan) and the data were processed by Spectra Manager system. The inhibition percentage of protein denaturation was calculated using the following formula:

% Denaturation inhibition = (1−D/C)×100%

Where D is the absorbance reading of the test sample, and C is the absorbance reading without test sample (negative control).

Total Phenolic Content (TPC) Analysis of B. racemosa

The TPC analysis using Follin-Ciocalteau method was carried out according to Almey et al. [20] with minor modifications in the duration of incubation before absorbance measurement being recorded which was altered to be 1 h (60 min). Gallic acid was used as a positive reference standard. The plant extracts as well as the positive standard were prepared as stock solutions at a concentration of 0.1% each (1.0 mg/ml). Working standards of between 0.01 and 0.05% were prepared for TPC analysis. The reaction vessels were prepared by placing 100 µL plant extract added with 750 µL Folin-Ciocalteu reagent in each vessel. The mixture was incubated at room temperature (25°C) for 5 min. Afterward, 750 µL of 6.0% (w/v) sodium carbonate was added into each reaction vessel and mixed thoroughly. The mixtures were incubated at room temperature (25°C) for 60 min before the absorbance of each sample was read at 765 nm by spectrophotometer (Thermo GENESYS™ 20 Visible Spectrophotometer, USA). The assays were done in triplicate. The standard calibration curve of gallic acid was plotted and used for the determination of TPC in the test samples. A linear equation was generated from the curve to identify related gallic acid concentration by substituting the corresponding absorbance value as “y” values in the equation to find the resulting concentration of gallic acid (mg/ml) as the “x” values. Afterward, the TPC of each plant sample was calculated according to the following formula. The results were expressed as mg GAE/g DW (mg gallic acid equivalent/g dry weight of extract):

TPC = (C) V/M

Where, TPC = Total phenolic content (mg GAE/g DW)

C = Concentration of GA from calibration curve linear equation (mg/ml)

V = Volume of the extract solution (ml)

M = Weight of extract used (g).

Statistical Analyses of Results

The results were expressed as mean ± standard deviation of triplicate readings and statistically analyzed by IBM SPSS Statistics version 17.0. The data were subjected to one-way analysis of variance. Tukey’s honest significant difference (HSD) test (P < 0.01) was performed to determine the significance of the difference between means of different plant part extracts.

RESULTS

Anti-inflammatory Activitiy Assays

XO inhibitory activity of B. racemosa

All extracts had shown more than 50% inhibition against XO activities [Table 1]. This signified that the extracts effectively inhibited XO from catalyzing the action of converting xanthine to uric acid at a considerably low concentration of 0.1%. The infloresence axes extract was found to exert the highest inhibition capacity at 0.1% (v/v) with 59.54 ± 0.001% inhibitory activity followed by leaves (58.82 ± 0.001%), pericarps (57.99 ± 0.003%), and endosperms (57.20 ± 0.003%) extracts. Meanwhile, the positive control, oxypurinol recorded 68.36% inhibition of XO activities at a relatively similar concentration.

Table 1.

The anti-inflammatory activities (in xanthine oxidase inhibitory and albumin denaturation assay) and TPC of different plant parts of B. racemosa

graphic file with name JIE-5-343-g003.jpg

Open in a new tab

Albumin denaturation inhibitory activity of B. racemosa

All extracts had given more than 50% inhibition [Table 1]. The infloresence axes extract had shown the greatest inhibition capacity with 70.58 ± 0.004% followed by endosperms (66.80 ± 0.024%), leaves (65.29 ± 0.006%), and pericarps extracts (43.33 ± 0.002%). Meanwhile, the non-steroidal anti-inflammatory drugs (NSAIDs) drugs used which were ibuprofen and diclofenac sodium exhibited relatively higher inhibition capacity of 83.53 ± 0.003% and 94.90 ± 0.004%, respectively.

TPC Analysis of B. racemosa

A calibration curve had been plotted using the absorbance data of gallic acid over serial concentrations [Figure 3]. An equation of y = 6.2500x + 0.0429 was obtained for its linear equation with the correlation value of R2 = 0.9944.

Figure 3.

Figure 3

Open in a new tab

Gallic acid calibration curve for Folin-Ciocalteu total phenolic content assay of Barringtonia racemosa

Different plant parts had given different TPC values in B. racemosa [Table 1] with the leading phenolic content was found in leaves extract (53.94 ± 0.000 mg GAE/g DW). This was followed by infloresence axes (31.54 ± 0.001 mg GAE/g DW), endosperms (22.63 ± 0.001 mg GAE/g DW) and the least was found in the pericarp part of fruits extracts (15.54 ± 0.001 mg GAE/g DW).

DISCUSSION

In Vitro Anti-inflammatory Activities

XO inhibitory activity of B. racemosa

According to a review by Borges et al. [21], XO is a type of enzyme which is ubiquitously found among species and tissues of mammals and it catalyzes the oxidative hydroxylation of purine substrates and subsequent reduction of O2 with generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide. In rheumatological diseases point of view, XO is an enzyme responsible for catalyzing the oxidation of hypoxanthine to xanthine and further lead to the formation of uric acid [22] in which the elevated beyond normal levels will be the underlying reason of gouty arthritis attack [23]. Even though XO is the factor which leads to the occurrence of gouty arthritis, there is an overwhelming acceptance that XO serum levels are significantly increased in various pathological states such as hepatitis, inflammation, ischemia-reperfusion, carcinogenesis, and aging [21].

The action of XO inhibitor is therefore required in the prevention and treatment of gout whereby it inhibits the biosynthesis of uric acid from purine [Figure 4] and allopurinol is the widely used synthetic XO inhibitor used in modern medicine in the treatment of gout [24]. Both allopurinol and its active metabolite, oxypurinol (isosteres of hypoxanthine and xanthine, respectively), inhibit XO. Their competitive inhibitions thereby limiting the biosynthesis of uric acid hence promoting renal clearance of hypoxanthine and xanthine [21,25].

Figure 4.

Figure 4

Open in a new tab

The reaction cascade of allopurinol in xanthine oxidase inhibition mechanism and uric acid biosynthesis in gouty arthritis pathogenesis

Nevertheless, allopurinol may exert certain side effects due to allergy and may generate rashes [18]. In serious cases, allopurinol may also lead to fatality due to adverse drug reactions attributed to allopurinol hypersensitivity [18,26]. Due to such reason, the search for natural sources of plant-based medicines with profound effects of XO inhibition activities is seen to be worthwhile.

Considering the present study, it had been proven that B. racemosa effectively inhibits XO activity which resulted in great inhibition percentage in the most optimum extract from the infloresence axes part (59.54 ± 0.001%) at a concentration of as low as 0.10%. Oxypurinol was used as a positive standard for XO inhibition in this study whereby it is known as an active metabolite of allopurinol; hence functions as an inhibitor of XO. Oxypurinol had shown greater XO inhibition by exerting 68.36 ± 0.003% inhibitory activity at a concentration of 0.1%. The linear equations generated from the dose-response plot of infloresence axes extract and oxypurinol were utilized to estimate the effective concentration for maximal inhibition in both samples. On value substitution, maximal inhibition (100%) in infloresence axes extract was estimated to be at a concentration of 1.07% (10.7 mg/ml) while oxypurinol exhibited 0.41% (4.10 mg/ml) as its estimated effective concentration for maximal XO inhibition. According to post-hoc analysis of Tukey HSD, there were significant differences (P < 0.01) between means of each sample in the XO inhibition activity.

The previous studies done on B. racemosa showed its protective effects against adjuvant-induced arthritis in animal models [8], and therefore, corroborated the potential use of this species to alleviate inflammatory symptoms in rheumatic-related diseases. In the study carried out by Patil et al. [8], the consumption of B. racemosa-derived bartogenic acid resulted in protection against primary and secondary arthritic lesions, body weight changes, and hematological pertubations. In addition, the serum markers of inflammation and arthritis in the arthritic rats were also reduced. On radiological analysis and pain score, the effectiveness of the species was found to be promising and protective against arthritis. Considering its effectiveness in rheumatological disorders, therefore in the current study the potential use of B. racemosa in alleviating gouty arthritis was being assessed since to date, there were neither in vivo nor in vitro studies had ever been recorded to evaluate its potential to be used as gouty remedies. In addition, according to toxicological studies done on B. racemosa, it had been verified that the species is devoid of toxicity [9,10] and may serve as a potential candidate to be further developed into a herbal-based formulation for gouty arthritis treatment.

Albumin denaturation inhibitory activity of B. racemosa

Inflammation is the reaction process of living tissues to stimuli evoked by inflammatory agents such as physical injuries, heat, microbial infections, and noxious chemical irritations. The response of cells toward inflammation will lead to certain pathological manifestations characterized by redness, heat, swelling, and pain with even impaired physiological functions. Inflammation has been implicated in the pathogenesis of many diseases including arthritis, stroke, and cancer [27]. Protein denaturation has been well correlated with the occurrence of the inflammatory response and leads to various inflammatory diseases including arthritis [28]. According to Opie [29], tissue injury during life might be referable to denaturation of the protein constituents of cells or of intercellular substance. Hence, the ability of a substance to inhibit the denaturation of protein signifies apparent potential for anti-inflammatory activity.

The capacity of different plant parts of B. racemosa to inhibit protein denaturation of albumin which was ranging from 43.33 ± 0.002% to 70.58 ± 0.004% inhibition in this assay had therefore provided another evidence for its promising anti-inflammatory properties. In the current study, ibuprofen and diclofenac sodium, the two routinely used NSAIDs for arthritis had been used as the reference compound anticipated to exert optimally positive inhibition percentage. A statistical analysis had shown that there were no significant differences (P > 0.01) between means of different plant parts except in pericarp, whereby the extract exhibited significant differences in multiple comparison analysis of post-hoc Tukey HSD test.

In clinical setting, major pharmacological agents used for the anti-inflammatory and pain-relief management are NSAIDs due to their capacity in inhibiting protein denaturation [30]. However, this type of drugs is associated with adverse effects on gastrointestinal tract leading to the formation of gastric ulcers and may result in cardiovascular complications as well [31-33]. Interestingly, B. racemosa had been documented to be used as a natural remedy for gastric ulcer as quoted by Hussin et al. [4] according to Deraniyagala et al. [9]. Indeed, this provides another added value for the species to be considered as a potential candidate for anti-inflammatory agent, deliberating the expectation that the risk of developing gastric ulcers could be minimized considering its ethnopharmacological use.

TPC Analysis of B. racemosa

Phenolics are broadly distributed in the plant kingdom and are the most abundant secondary metabolites of plants [34]. Due to such reason, high intake of fruits and vegetables in daily diet are being recommended. Apart from being frequently associated with anti-oxidative properties [35], the presence of phenolic compounds in plants has been attributed to a number of significant pharmacological activities for instance as a cancer cell growth and development inhibitor [36-38], as natural antiulcer due to their gastroprotective nature [39] and providing pain relief for arthritis-related diseases [40].

In this study, the highest TPC was found in the extract of leaves followed in descending order by infloresence axes, endosperms, and pericarps. The ex vitro leaves extract of B. racemosa had demonstrated the greatest content of phenolic compounds (53.94 ± 0.000 mg GAE/g DW) and the least was found in the pericarp part of fruits (15.54 ± 0.001 mg GAE/g DW). The differences between means of plant parts in this TPC study were statistically significant (P < 0.01) according to post-hoc Tukey HSD test.

It has been observed that the values of TPC from the samples in the current research recorded greater phenolic content from those documented in the previous researches. Nurul-Mariam et al. [12] reported that the highest TPC was obtained from the methanolic extract of a stick of B. racemosa which recorded the value of 29.9 ± 0.02 mg GAE/g freeze dried weight. Meanwhile, Zawawi et al. [41] were investigated the value of TPC of B. racemosa in methanolic extract of young leaves, and the TPC value of the most optimum samples was found to be relatively low (0.34 mg GAE/g DW) as compared to that of TPC obtained from the current research. The differences in the findings could be due to many factors and may be affected by genotype, plant age, and developmental stages as well as sample preparation procedures.

Another point to be highlighted in the present study is the superiority of infloresence axis in its anti-inflammatory activities among other plant parts in both anti-inflammatory assays. It has been noted that even though the infloresence axis part was having the greatest anti-inflammatory activities; nevertheless in terms of plant phenolic content, its superiority was lower than leaves extract. Therefore, it could be suggested that the anti-inflammatory activities shown by the infloresence axes extract were possibly not solely due to the phenolic content of the species. The activities were, therefore, could be anticipated to be influenced by any other factors such as fatty acids compositions. The findings were almost similarly portrayed in Jatropha curcas L. in which the roots sample of J. curcas showed the highest anti-inflammatory activity but contained lower phenolic compounds than the leaves extract [42].

Nevertheless, more further studies are underway to investigate the distinctive presence of phenolic compounds in B. racemosa since it has been reported by Hussin et al. [4] that there was significant detection of phenolic compounds in the species (leaf, stick and bark parts) by using high performance liquid chromatography analysis. Therefore, this indeed requires further analyses to elucidate the compounds responsible for B. racemosa’s anti-inflammatory activities.

CONCLUSION

This study showed promising properties of B. racemosa to be potentially used as a plant-derived anti-gouty arthritis remedy. The superior activities of infloresence axis had shown its potential to be optimally harnessed as a candidate in the mitigation of inflammatory diseases. Due to its XO inhibitory activity, this species would be useful in preventing the progress of other XO-related diseases as well. It is suggested that intense in vivo studies to be conducted to determine the amount recommended for consumption. Owing to its pharmacological importances, further studies and investigations are therefore required for this species to be optimally developed as pharmaceutical preparations in alleviating inflammation.

Footnotes

Source of Support: Nil,

Conflict of Interest: None declared.

REFERENCES

  • 1.Perrone A, Piacente S, Rastrelli L, Dugo G. Sample preparation analytical methods and chemical standardization of medicinal plants. In: Bagetta G, Cosentino M, Corasaniti MT, Sakurada S, editors. Herbal Medicines Development and Validation of Plant-Derived Medicines for Human Health. Boca Raton: CRC Press Taylor & Francis Group; 2012. pp. 93–136. [Google Scholar]
  • 2.Osman NI, Sidik NJ, Awal A. Pharmacological activities of Barringtonia racemosa L. (Putat), a tropical medicinal plant species. J Pharm Sci Res. 2015;7:185–8. [Google Scholar]
  • 3.Khan S, Jabbar A, Hasan CM, Rashid MA. Antibacterial activity of Barringtonia racemosa. Fitoterapia. 2001;72:162–4. doi: 10.1016/s0367-326x(00)00264-1. [DOI] [PubMed] [Google Scholar]
  • 4.Hussin NM, Muse R, Ahmad S, Ramli J, Mahmood M, Sulaiman MR, et al. Antifungal activity of extracts and phenolic compounds from Barringtonia racemosa L. (Lecythidaceae) Afr J Biotechnol. 2009;8:2835–42. [Google Scholar]
  • 5.Saha S, Sarkar KK, Hossain ML, Hossin A, Barman AK, Ahmed MI, et al. Bioactivity studies on Barringtonia racemosa (Lam.). bark. Pharmacologyonline. 2013;1:93–100. [Google Scholar]
  • 6.Mmushi T, Masoko P, Mdee L, Mokgotho M, Mampuru Lj, Howard R. Antimycobacterial evaluation of fifteen medicinal plants in South Africa. Afr J Tradit Complement Altern Med. 2009;7:34–9. doi: 10.4314/ajtcam.v7i1.57230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Thomas TJ, Panikkar B, Subramoniam A, Nair MK, Panikkar KR. Antitumour property and toxicity of Barringtonia racemosa Roxb seed extract in mice. J Ethnopharmacol. 2002;82:223–7. doi: 10.1016/s0378-8741(02)00074-0. [DOI] [PubMed] [Google Scholar]
  • 8.Patil KR, Patil CR, Jadhav RB, Mahajan VK, Patil PR, Gaikwad PS. Anti-arthritic activity of bartogenic acid isolated from fruits of Barringtonia racemosa Roxb. (Lecythidaceae) Evid Based Complement Alternat Med. 2011;2011:785245. doi: 10.1093/ecam/nep148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Deraniyagala SA, Ratnasooriya WD, Goonasekara CL. Antinociceptive effect and toxicological study of the aqueous bark extract of Barringtonia racemosa on rats. J Ethnopharmacol. 2003;86:21–6. doi: 10.1016/s0378-8741(03)00015-1. [DOI] [PubMed] [Google Scholar]
  • 10.Shikha P, Latha PG, Suja SR, Anuja GI, Shyamal S, Shine VJ, et al. Anti-inflammatory and analgesic activity of Barringtonia racemosa Roxb. Fruits. Indian J Nat Prod Resour. 2010;1:356–61. [Google Scholar]
  • 11.Behbahani M, Ali AM, Muse R, Mohd NB. Anti-oxidant and anti-inflammatory activities of leaves of Barringtonia racemosa. J Med Plant Res. 2007;1:95–102. [Google Scholar]
  • 12.Nurul-Mariam H, Radzali M, Johari R, Syahida A, Maziah M. Antioxidant activities of different aerial parts of putat (Barringtonia racemosa L.) Malays J Biochem Mol Biol. 2008;16:15–9. [Google Scholar]
  • 13.Kong KW, Sarni MJ, Aminuddin N, Ismail A, Azlina AA. Antioxidant activities and polyphenolics from the shoots of Barringtonia racemosa (L.). Spreng in a polar to apolar medium system. Food Chem. 2012;134:324–32. [Google Scholar]
  • 14.Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1987;1:89–96. [PubMed] [Google Scholar]
  • 15.Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:1–11. doi: 10.1186/ar3199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kew Royal Botanic Garden. Glossary of Botanical Term. [Last accessed on 2016 Apr, 10]. Available from: http://www.kew.org/science/tropamerica/neotropikey/families/glossary.htm# .
  • 17.Prance GT. Notes on Lecythidaceae of Peninsular Malaysia. Blumea. 2010;55:14–7. [Google Scholar]
  • 18.Azmi SM, Jamal P, Amid A. Xanthine oxidase inhibitory activity from potential Malaysian medicinal plant as remedies for gout. Int Food Res J. 2012;19:159–65. [Google Scholar]
  • 19.Kumari S, Yasmin N, Hussain MR, Babuselvam M. In vitro anti-inflammatory and anti-arthritic property of Rhizopora mucronata leaves. IJPSR. 2015;6:482–5. [Google Scholar]
  • 20.Almey AA, Khan CA, Zahir IS, Suleiman KM, Aisyah MR, Rahim KK. Total phenolic content and primary antioxidant activity of methanolic and ethanolic extracts of aromatic plants’ leaves. Int Food Res J. 2010;17:1077–84. [Google Scholar]
  • 21.Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002;9:195–217. doi: 10.2174/0929867023371229. [DOI] [PubMed] [Google Scholar]
  • 22.Ramallo IA, Zacchino SA, Furlan RL. A rapid TLC autographic method for the detection of xanthine oxidase inhibitors and superoxide scavengers. Phytochem Anal. 2006;17:15–9. doi: 10.1002/pca.874. [DOI] [PubMed] [Google Scholar]
  • 23.Virsaladze DK, Tetradze LO, Dzhavashvili LV, Esaliia NG, Tananashvili DE. Levels of uric acid in serum in patients with metabolic syndrome. Georgian Med News. 2007:35–7. [PubMed] [Google Scholar]
  • 24.Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114. doi: 10.1124/pr.58.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Trabsa H, Baghiani A, Boussoualim N, Krache I, Khennouf S, Charef N, et al. Kinetics of Inhibition of xanthine oxidase by Lycium arabicum and its protective effect against oxonate-induced hyperuricemia and renal dysfunction in mice. Trop J Pharm Res. 2015;14:249–56. [Google Scholar]
  • 26.Umpiérrez A, Cuesta-Herranz J, De Las Heras M, Lluch-Bernal M, Figueredo E, Sastre J. Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immunol. 1998;101:286–7. doi: 10.1016/S0091-6749(98)70396-3. [DOI] [PubMed] [Google Scholar]
  • 27.Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000. doi: 10.1161/ATVBAHA.110.207449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mizushima Y. Screening test for antirheumatic drugs. Lancet. 1966;288:443. [Google Scholar]
  • 29.Opie EL. On the relation of necrosis and inflammation to denaturation of proteins. J Exp Med. 1962;115:597–608. doi: 10.1084/jem.115.3.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Saso L, Valentini G, Casini ML, Grippa E, Gatto MT, Leone MG, et al. Inhibition of heat-induced denaturation of albumin by nonsteroidal antiinflammatory drugs (NSAIDs): Pharmacological implications. Arch Pharm Res. 2001;24:150–8. doi: 10.1007/BF02976483. [DOI] [PubMed] [Google Scholar]
  • 31.Arroyo M, Lanas A. NSAIDs-induced gastrointestinal damage. Review. Minerva Gastroenterol Dietol. 2006;52:249–59. [PubMed] [Google Scholar]
  • 32.Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: Current clinical management and recommendations for prevention. Chin J Dig Dis. 2006;7:127–33. doi: 10.1111/j.1443-9573.2006.00257.x. [DOI] [PubMed] [Google Scholar]
  • 33.Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121–32. doi: 10.1016/j.bpg.2009.11.005. [DOI] [PubMed] [Google Scholar]
  • 34.Dai J, Mumper RJ. Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. Molecules. 2010;15:7313–52. doi: 10.3390/molecules15107313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Norrizah JS, Hashim SN, Fasiha FS, Yaseer SM. b-carotene and antioxidant analysis of three different rockmelon (Cucumis melo L.) cultivar. J Applied Sci. 2012;12:1846–52. [Google Scholar]
  • 36.Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, et al. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2:659–68. [PubMed] [Google Scholar]
  • 37.Ranelletti FO, Maggiano N, Serra FG, Ricci R, Larocca LM, Lanza P, et al. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000;85:438–45. [PubMed] [Google Scholar]
  • 38.Elattar TM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res. 2000;20:1733–8. [PubMed] [Google Scholar]
  • 39.Maity B, Chattopadhyay S. Natural antiulcerogenic agents: An overview. Curr Bioact Compd. 2008;4:225–44. [Google Scholar]
  • 40.Alam MN, Rahman MM, Khalil MI. Nutraceuticals in arthritis management: A contemporary prospect of dietary phytochemicals. Open Nutraceuticals J. 2014;7:21–7. [Google Scholar]
  • 41.Zawawi DD, Jaafar H, Ali AM. Antioxidant properties and total phenolic content in different development stages of Barringtonia racemosa and Barringtonia spicata leaves. Walailak J Sci Technol. 2015;12:449–58. [Google Scholar]
  • 42.Othman AR, Abdullah N, Ahmad S, Ismail IS, Zakaria MP. Elucidation of in vitro anti-inflammatory bioactive compounds isolated from Jatropha curcas L. plant root. BMC Complement Altern Med. 2015;15:11. doi: 10.1186/s12906-015-0528-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Intercultural Ethnopharmacology are provided here courtesy of SAGEYA

RESOURCES